bluebird bio Launches Gene Therapy for Severe Blood Disorder in Germany | North Carolina Biotechnology Center
bluebird bio | LinkedIn
With the pricing situation 'untenable' in Europe, bluebird will wind down its operations in the 'broken' market
bluebird bio Office Photos | Glassdoor
Our Leadership Team | bluebird bio
bluebird bio Office Photos | Glassdoor
bluebird bio Office Photos | Glassdoor
blue-ex991_25.htm
Bluebird Bio still in thick of sickle cell race, as updated data allay safety concerns
bluebird bio to Present at the 31st Annual Credit Suisse Healthcare Conference | Business Wire
Contact Us | bluebird bio
Bluebird Bio nabs its 2nd gene therapy approval: The $3M Skysona
Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies | Business Wire
Stephen Dicker - Senior Director - bluebird bio | LinkedIn
bluebird bio Durham Office | Glassdoor
Our Leadership Team | bluebird bio
Roche's Spark Therapeutics, bluebird resolve suit on sickle cell disease 'Spark' campaign | Seeking Alpha
SEC Filing - bluebird bio, Inc.
Two positive AdCom votes for bluebird bio encouraging for gene therapies
bluebird bio Announces EU Conditional Marketing Authorization for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype
bluebird bio wins back-to-back landmark FDA approvals for first-in-class gene therapies - Pharmaceutical Technology
Bluebird Bio tabs Joseph Vittiglio as chief business and legal officer
Gene therapy: talking smart solutions with Bluebird Bio - Pharma Technology Focus | Issue 74 | September 2018
bluebird bio Office Photos | Glassdoor
